Description
Troglitazone, PPARγ agonist, is an anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity, which was approved for the treatment of insulin resistance and hyperglycemia in Type II diabetes, but was withdrawn from the market due to hepatotoxicity. It binds to the PPARγ ligand-binding domain (LBD) but fails to induce interaction of the PPARγ LBD with the transcriptional coactivators SRC-1, TIF2, AIB1, p300, or TRAP220. It also induces cell cycle arrest and apoptosis in several cancer cell lines. It displays no activity at PPARα or PPARδ receptors and displays anti-invasive effect on human breast cancer cells. It also inhibits cell growth of hematopoietic cell lines and inhibits lamellipodia formation and actin polymerization